Evidence map›Paper›PMID 30809504›Full record

ArticleJournal of epilepsy research2018

Endosulfan-Induced Prolonged Super-Refractory Status Epilepticus.

Hea Ree Park, Pamela Song, Jae Jung Lee, Joong-Yang Cho

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Journal of epilepsy research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Novel test strategies for in vitro seizure liability assessment.Expert opinion on drug metabolism & toxicology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hea Ree ParkDepartment of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Pamela SongDepartment of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Jae Jung LeeDepartment of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Joong-Yang ChoDepartment of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Inje University Ilsan Paik Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endosulfan is a highly toxic pesticide that causes hyperstimulation of the central nervous system by antagonizing gamma aminobutyric acid-mediated inhibition. Seizure is the most important manifestation of endosulfan poisoning, frequently progressing to status epilepticus and refractory status epilepticus. Here, we report a recent case of a 64-year-old man with endosulfan-induced super-refractory status epilepticus, which persisted for a remarkably longer period than has been described in previous reports. The patient arrived at the emergency room with continuous generalized tonic-clonic seizures. Electroencephalogram-recorded seizures that persisted even after intravenous administration of lorazepam and antiepileptic drugs. Intravenous anesthetic agents were administered for 9 days to confront the persistently recurring seizures. Immediately after this treatment period, the seizures subsided, and the patient showed marked neurological improvement. After 2 months however, he died of multiple systemic complications. This case report elucidates the importance of aggressive evaluation and management including continuous EEG monitoring in cases of endosulfan-related status epilepticus.

Indexed as

Endosulfan-induced super-refractory statusEndosulfan poisoningIntoxicationSeizureStatus epilepticus

Identifiers

PMID30809504
PMCPMC6374535
OpenAlexW2914760683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.